The Advisory Committee on Immunization Practices (ACIP) recommendations have been updated for the meningococcal serogroup B MenB-4C vaccine (Bexsero), in accordance with the updated U.S. Food and Drug ...
The Food and Drug Administration recently approved Novartis’ meningitis B vaccine, Bexsero, which had been used to vaccinate University students. The vaccine is now approved for use in 10- to ...
Please provide your email address to receive an email when new articles are posted on . The finding builds on a report last year from researchers in New Zealand that a discontinued meningococcal B ...
With today`s approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide Bexsero`s two-dose regimen offers a flexible dosing ...
GlaxoSmithKline is reporting encouraging rates of efficacy from the world's first national meningitis B immunisation programme with Bexsero, a year after its UK launch. GlaxoSmithKline is reporting ...
GlaxoSmithKline is bringing its mom squad back to primetime. The “Moms Against Meningitis B” spot, a promo for GSK's vaccine Bexsero, is back on TV this month just in time for back-to-college, albeit ...
Basel, July 29, 2014 - Novartis has announced the initial results of a large-scale vaccination campaign with Bexsero ® (Meningococcal Group B Vaccine [rDNA, component, adsorbed]) to help protect ...
Good news for GlaxoSmithKline, and those U.K. parents wanting to get their hands on its meningitis B vaccine, Bexsero: The wait is over. Glaxo will have a global shortage resolved by next month, it ...
Novartis got a major boost to its vaccines division yesterday after winning EU approval for Bexsero, its much-anticipated new meningitis B vaccine. A green light from the European Medicines Agency ...
Please provide your email address to receive an email when new articles are posted on . The FDA today approved the recombinant vaccine, Bexsero, for prevention of Neisseria meningitidis serogroup B ...
Most Australian parents will be unable to buy a vaccine for the B strain of the dangerous meningococcal disease until the new year. Pharmaceutical company GlaxoSmithKline said increasing global demand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results